副神經節瘤市場規模、佔有率和成長分析：按部位、疾病類型、診斷方法、給藥途徑、治療方法、分銷管道、最終用戶和地區分類 - 行業預測，2026-2033 年

2024 年全球副神經節瘤市值為 3.658 億美元，預計到 2033 年將成長至 4.4104 億美元，而 2025 年為 3.7348 億美元，預測期（2026-2033 年）的複合年成長率為 2.1%。

全球副神經節瘤市場專注於罕見神經內分泌腫瘤的診斷和治療解決方案，這些腫瘤起源於副神經節，以其兒茶酚胺的產生而聞名。由於延遲診斷會導致嚴重的併發症，該領域正日益受到業界的關注，尤其是在SDHx突變等突破性發現出現之後。功能性影像和放射性藥物（包括碘苯甲胺I-131和68Ga PET）的進步正在改變傳統的治療方法，從而提高檢測能力並活性化臨床試驗的發展。先進的分子診斷和標靶治療的整合正在推動市場成長並創造眾多商機。此外，人工智慧技術透過改進影像和基因組分析，簡化了診斷和治療決策，促進了臨床實踐中的協作並最佳化了患者的治療效果。

全球副神經節瘤市場成長要素

全球副神經節瘤市場正受到影像技術進步的顯著影響，這些進步提高了檢測這種罕見腫瘤的準確性和靈敏度。這些創新實現了早期診斷和更精確的腫瘤定位，從而擴大了適用多種治療方法的患者群體。隨著檢測能力的提升，臨床醫師更有信心推薦標靶治療，進而帶動了對診斷服務和相關治療需求的成長。此外，影像技術的進步有助於做出明智的臨床決策，並促進綜合治療策略的整合。這促使醫療服務提供者和製造商加大對診斷和治療創新技術的投資，從而推動全球市場的成長。

全球副神經節瘤市場的限制因素

全球副神經節瘤市場面臨的主要限制因素之一是全科醫生和部分專科醫生對該疾病的認知和了解有限。這導致診斷延誤和患者轉診不足。這種情況導致轉診至專科的患者減少，最終降低了對影像學檢查、分子檢測和標靶治療等關鍵服務的需求。人們普遍認為該疾病的臨床重要性較低，這構成了一大障礙，可能使醫療專業人員和行業相關人員不願在該領域投入資源。此外，對副神經節瘤認知不足限制了多學科卓越醫療中心的建立，並阻礙了創新治療方法的引入，所有這些因素共同阻礙了市場成長。

全球副神經節瘤市場趨勢

由於整合式精準診斷技術的引入，全球副神經節瘤市場正經歷顯著的變革，這些技術正在革新臨床診療路徑。這一趨勢強調結合分子譜分析、先進影像技術和多學科協作，以提高診斷準確性並促進更精準的患者分層。診斷創新者與醫療中心之間的合作旨在建立標準化通訊協定，從而加速生物標記發現並應用於臨床實踐。這些進展不僅提高了診斷的清晰度，還支持個人化治療策略，推動對平台技術的投資，並促進在專科和社區醫療機構中優先考慮無縫患者照護和一致治療方案的夥伴關係。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 案例研究
• 專利分析

全球副神經節瘤市場規模：依發生部位分類

• 頭部和頸部
• 腹部
• 骨盆
• 其他

全球副神經節瘤市場規模：依疾病類型分類

• 交感神經節瘤
• 副交感神經節瘤
• 頸動脈副神經節瘤
• 子宮頸副神經節瘤
• 頸靜脈副神經節瘤
• 分泌性副神經節瘤
• 其他

全球副神經節瘤市場規模：依診斷方法分類

• 診斷影像（電腦斷層掃描、MRI、PET掃描）
• 生物化學檢驗
• 基因檢測
• 其他

全球副神經節瘤市場規模：依給藥途徑分類

• 口服
• 注射藥物

全球副神經節瘤市場規模：依治療方法分類

• 外科手術
• 放射線治療
• 胜肽受體療法
• 化療
  • 治療藥物
• 標靶治療

全球副神經節瘤市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 其他

全球副神經節瘤市場規模：依最終用戶分類

• 醫院
• 專科診所
• 癌症研究機構

全球副神經節瘤市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Progenics Pharmaceuticals Inc.
• AstraZeneca
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd
• Advanced Accelerator Applications
• Cipla Inc.
• Fresenius Kabi AG
• Amgen Inc.
• Merck & Co., Inc.
• GSK（GlaxoSmithKline）
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Incyte Corporation
• Sumitomo Dainippon Pharma Co., Ltd.
• Mitsubishi Tanabe Pharma Corporation
• BeiGene, Ltd.
• Athenex, Inc.
• Regeneron Pharmaceuticals, Inc.

結論與建議

Global Paraganglioma Market size was valued at USD 365.8 Million in 2024 and is poised to grow from USD 373.48 Million in 2025 to USD 441.04 Million by 2033, growing at a CAGR of 2.1% during the forecast period (2026-2033).

The global paraganglioma market is focused on diagnostics and treatment solutions for rare neuroendocrine tumors derived from paraganglia, known for catecholamine production. Due to the significant morbidity associated with late diagnoses, this sector is gaining heightened industry focus, especially as innovative discoveries like SDHx mutations emerge. Advancements in functional imaging and radiopharmaceuticals, including iobenguane I 131 and 68Ga DOTATATE PET, are transforming traditional management approaches, leading to enhanced detection and increased clinical trial activities. The integration of advanced molecular diagnostics and targeted therapies fuels market growth, creating numerous commercial opportunities. Furthermore, AI technologies are streamlining diagnosis and treatment decisions through improved imaging analysis and genomic interpretation, fostering collaborative efforts in clinical environments and optimizing patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Paraganglioma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Paraganglioma Market Segments Analysis

Global paraganglioma market is segmented by origin, disease type, diagnosis method, route of administration, therapy, distribution channel, end-user and region. Based on origin, the market is segmented into Head & Neck, Abdomen, Pelvis and Others. Based on disease type, the market is segmented into Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Carotid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas and Others. Based on diagnosis method, the market is segmented into Imaging (CT Scan, MRI, PET Scan), Biochemical Testing, Genetic Testing and Others. Based on route of administration, the market is segmented into Oral and Injectable. Based on therapy, the market is segmented into Surgery, Radiation Therapy, Peptide Receptor Therapy, Chemotherapy and Targeted Therapy. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on end-user, the market is segmented into Hospitals, Specialty Clinics and Cancer Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Paraganglioma Market

The global market for paraganglioma is significantly influenced by advancements in imaging technologies, which improve the accuracy and sensitivity of detecting this rare tumor. These innovations lead to earlier diagnoses and more precise localization of tumors, broadening the patient demographic suitable for various interventions. With enhanced detection capabilities, clinicians are more confident in recommending targeted therapies, effectively increasing the demand for both diagnostic services and associated treatments. Furthermore, improved imaging aids in making informed clinical decisions and fosters the integration of comprehensive care strategies, prompting healthcare providers and manufacturers to invest in diagnostic and therapeutic innovations that propel global market growth.

Restraints in the Global Paraganglioma Market

One significant restraint in the global paraganglioma market is the limited awareness and understanding of the condition among general practitioners and certain specialists, leading to delays in diagnosis and under-referral of patients. This situation results in fewer patients being directed toward specialized care, ultimately decreasing demand for essential services such as diagnostic imaging, molecular testing, and targeted therapies. The perceived lack of clinical importance creates barriers that may dissuade healthcare providers and industry players from dedicating resources to this area. Furthermore, insufficient recognition of paraganglioma limits the development of multidisciplinary centers of excellence and hinders the adoption of innovative treatment methods, which collectively impede market growth.

Market Trends of the Global Paraganglioma Market

The Global Paraganglioma market is witnessing a significant shift through the adoption of precision diagnostic integration, which is revolutionizing clinical pathways. This trend emphasizes the combination of molecular profiling, advanced imaging techniques, and multidisciplinary reviews to enhance diagnostic accuracy and facilitate better patient stratification. Collaborative efforts between diagnostic innovators and healthcare centers aim to establish standardized protocols, allowing for quicker implementation of biomarker discoveries into clinical practice. Such advancements not only bolster diagnostic clarity but also support personalized therapeutic strategies, driving investments in platform technologies and fostering partnerships that prioritize seamless patient care and consistent treatment planning across specialized and community healthcare settings.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Case Studies
• Patent Analysis

Global Paraganglioma Market Size by Origin & CAGR (2026-2033)

• Market Overview
• Head & Neck
• Abdomen
• Pelvis
• Others

Global Paraganglioma Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Sympathetic Paragangliomas
• Parasympathetic Paragangliomas
• Carotid Paragangliomas
• Cervical Paragangliomas
• Jugular Paragangliomas
• Secretory Paragangliomas
• Others

Global Paraganglioma Market Size by Diagnosis Method & CAGR (2026-2033)

• Market Overview
• Imaging (CT Scan, MRI, PET Scan)
• Biochemical Testing
• Genetic Testing
• Others

Global Paraganglioma Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Paraganglioma Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Surgery
• Radiation Therapy
• Peptide Receptor Therapy
• Chemotherapy
  • Therapeutic Drugs
• Targeted Therapy

Global Paraganglioma Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Paraganglioma Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Cancer Research Institutes

Global Paraganglioma Market Size & CAGR (2026-2033)

• North America (Origin, Disease Type, Diagnosis Method, Route of Administration, Therapy, Distribution Channel, End-User)
  • US
  • Canada
• Europe (Origin, Disease Type, Diagnosis Method, Route of Administration, Therapy, Distribution Channel, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Origin, Disease Type, Diagnosis Method, Route of Administration, Therapy, Distribution Channel, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Origin, Disease Type, Diagnosis Method, Route of Administration, Therapy, Distribution Channel, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Origin, Disease Type, Diagnosis Method, Route of Administration, Therapy, Distribution Channel, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Progenics Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athenex, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations